We provide pre-clinical in vitro data that cutaneous T cell lymphoma cells are specifically sensitive towards 4SC-202, a compound previously described as a dual inhibitor targeting type I HDACs as well as LSD1. This evidence concerns the gene KDM1A and primary cutaneous T-cell non-Hodgkin lymphoma.